U.S. Food and Drug Administration Office of Special Medical Programs
E886016
The U.S. Food and Drug Administration Office of Special Medical Programs is an FDA office that oversees cross-cutting medical policy initiatives and specialized regulatory programs to ensure the safety and effectiveness of medical products.
All labels observed (1)
| Label | Occurrences |
|---|---|
| U.S. Food and Drug Administration Office of Special Medical Programs canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T10790397 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: U.S. Food and Drug Administration Office of Special Medical Programs Context triple: [White Oak, Maryland, isNearFederalFacility, U.S. Food and Drug Administration Office of Special Medical Programs]
-
A.
Office of Orphan Products Development
The Office of Orphan Products Development is a U.S. Food and Drug Administration office that promotes the development of drugs and other medical products for rare diseases and conditions.
-
B.
Office of Regulatory Affairs
The Office of Regulatory Affairs is the U.S. FDA’s primary field organization responsible for inspecting regulated products and manufacturers, enforcing compliance, and overseeing import operations to protect public health.
-
C.
FDA CFSAN
FDA CFSAN is the U.S. Food and Drug Administration’s center responsible for regulating the safety, labeling, and nutritional quality of foods, dietary supplements, and cosmetics.
-
D.
Center for Drug Evaluation and Research
The Center for Drug Evaluation and Research is the U.S. FDA division responsible for overseeing the safety, effectiveness, and quality of prescription and over-the-counter drugs.
-
E.
Center for Biologics Evaluation and Research
The Center for Biologics Evaluation and Research is the U.S. regulatory body responsible for overseeing the safety, efficacy, and quality of biological products such as vaccines, blood products, and gene therapies.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: U.S. Food and Drug Administration Office of Special Medical Programs Target entity description: The U.S. Food and Drug Administration Office of Special Medical Programs is an FDA office that oversees cross-cutting medical policy initiatives and specialized regulatory programs to ensure the safety and effectiveness of medical products.
-
A.
Office of Orphan Products Development
The Office of Orphan Products Development is a U.S. Food and Drug Administration office that promotes the development of drugs and other medical products for rare diseases and conditions.
-
B.
Office of Regulatory Affairs
The Office of Regulatory Affairs is the U.S. FDA’s primary field organization responsible for inspecting regulated products and manufacturers, enforcing compliance, and overseeing import operations to protect public health.
-
C.
FDA CFSAN
FDA CFSAN is the U.S. Food and Drug Administration’s center responsible for regulating the safety, labeling, and nutritional quality of foods, dietary supplements, and cosmetics.
-
D.
Center for Drug Evaluation and Research
The Center for Drug Evaluation and Research is the U.S. FDA division responsible for overseeing the safety, effectiveness, and quality of prescription and over-the-counter drugs.
-
E.
Center for Biologics Evaluation and Research
The Center for Biologics Evaluation and Research is the U.S. regulatory body responsible for overseeing the safety, efficacy, and quality of biological products such as vaccines, blood products, and gene therapies.
- F. None of above. chosen
Statements (15)
| Predicate | Object |
|---|---|
| instanceOf |
FDA office
ⓘ
government organization unit ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| jurisdiction | federal ⓘ |
| locatedIn |
Silver Spring, Maryland (FDA headquarters)
NERFINISHED
ⓘ
United States of America ⓘ
surface form:
United States
|
| oversees |
cross-cutting medical policy initiatives
ⓘ
specialized regulatory programs ⓘ |
| parentAgency | U.S. Department of Health and Human Services NERFINISHED ⓘ |
| partOf | U.S. Food and Drug Administration NERFINISHED ⓘ |
| regulatoryGoal |
ensure effectiveness of medical products
ⓘ
ensure safety of medical products ⓘ |
| regulatoryScope | medical products ⓘ |
| sector |
medical product regulation
ⓘ
public health ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: U.S. Food and Drug Administration Office of Special Medical Programs Description of subject: The U.S. Food and Drug Administration Office of Special Medical Programs is an FDA office that oversees cross-cutting medical policy initiatives and specialized regulatory programs to ensure the safety and effectiveness of medical products.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
White Oak, Maryland
→
isNearFederalFacility
→
U.S. Food and Drug Administration Office of Special Medical Programs
ⓘ